GI Signals · Trends

The digest, over time.

Charts from the 20 published issues so far: how selective it stays, which areas are busy, and what moves the standard of care.

01 / OVER TIME

How selective it stays

Papers surfaced as a share of papers screened, each week (oldest first). It should stay low and steady.

0%10%20%30%40%50%Surfaced %7%06/24/269%16%37%07/26/2631%34%28%08/16/2629%33%33%09/06/2631%38%29%09/27/2636%42%30%10/18/2633%33%26%11/08/2634%11/15/26
02 / OVER TIME

Which areas are busy

Surfaced papers by subspecialty, week by week (oldest at left). A busy section or a quiet stretch shows up week to week.

06/24/26
07/12/26
07/19/26
07/26/26
08/02/26
08/09/26
08/16/26
08/23/26
08/30/26
09/06/26
09/13/26
09/20/26
09/27/26
10/04/26
10/11/26
10/18/26
10/25/26
11/01/26
11/08/26
11/15/26
IBD
5
1
5
6
19
9
5
11
6
24
9
6
9
21
13
5
11
19
17
14
Hepatology
2
5
4
12
36
14
9
6
15
30
16
18
15
38
20
10
12
32
8
14
Esophagus/Reflux
2
2
2
4
5
1
6
5
3
3
2
8
4
6
2
4
3
4
Pancreas/Biliary
3
2
5
2
11
5
3
6
5
10
3
6
4
9
5
4
6
6
8
5
Endoscopy
5
5
4
21
18
16
8
8
13
15
10
13
8
10
14
7
8
9
8
10
Motility
4
5
7
9
3
3
5
2
6
1
1
6
4
6
5
6
7
1
Colorectal
5
2
1
3
9
5
2
3
9
1
2
6
6
10
7
4
6
10
5
Nutrition
3
2
3
2
3
2
2
2
1
2
3
3
4
2
03 / OVER TIME

How much each week shifts the standard

Mean standard-shift by week, oldest first (1 reinforces current practice, 5 challenges it). A busy week reads differently from a quiet one.

12345Mean shift3.306/24/262.12.61.907/26/261.52.12.108/16/262.31.51.609/06/262.51.81.709/27/261.61.61.610/18/261.71.81.611/08/261.511/15/26
04 / OVER TIME

Which journals show up most

Cumulative surfaced papers by journal: the journals that carry the signal, week after week.

Inflamm Bowel Dis95
Clin Gastro Hep82
Liver International73
J Gastro Hep58
Gut55
Aliment Pharm Ther52
Dig Dis Sci50
J Clin Gastro49
05 / OVER TIME

The run so far

One tile per week (oldest first): how many papers surfaced and the spread of their signal scores.

06/24/26 · #1
29surfaced
score 7 to 92
07/12/26 · #2
17surfaced
score 32 to 80
07/19/26 · #3
28surfaced
score 37 to 83
07/26/26 · #4
58surfaced
score 32 to 80
08/02/26 · #5
107surfaced
score 35 to 87
08/09/26 · #6
52surfaced
score 32 to 79
08/16/26 · #7
28surfaced
score 16 to 79
08/23/26 · #8
41surfaced
score 40 to 88
08/30/26 · #9
53surfaced
score 38 to 95
09/06/26 · #10
101surfaced
score 36 to 89
09/13/26 · #11
45surfaced
score 37 to 92
09/20/26 · #12
51surfaced
score 37 to 86
09/27/26 · #13
50surfaced
score 36 to 82
10/04/26 · #14
97surfaced
score 35 to 88
10/11/26 · #15
74surfaced
score 36 to 91
10/18/26 · #16
47surfaced
score 38 to 88
10/25/26 · #17
46surfaced
score 37 to 92
11/01/26 · #18
86surfaced
score 35 to 83
11/08/26 · #19
61surfaced
score 36 to 87
11/15/26 · #20
55surfaced
score 28 to 79
06 / THIS ISSUE

The signal map

Every surfaced paper placed by evidence strength and clinical utility; dot size is the journal's impact factor, and a dark ring marks a paper that refines or changes its standard. Top right is the week's must-read.

306191narrative reviewmeta-analysis →Clinical utilityEvidence strength
07 / THIS ISSUE

What drove each score

The top papers, each split into the four scoring parts, so you can see why a paper ranked without opening its card.

Mucosal abnormalities as key predictive factors of colorectal cancer in ulcerative colitis.75
Colonoscopy outcomes after positive multi-target stool DNA testing in patients with and without a prior normal colonoscopy: Data from the New Hampshire Colonoscopy Registry.79
Oral Anticoagulant Choice Across Indications in Cirrhosis: A US Nationwide Cohort Study.79
Efficacy and safety of dabigatran in cirrhosis with chronic portal vein thrombosis: A randomized, placebo-controlled double-blind trial (DAB-PVT).79
Impact of Guideline-Based Acute Kidney Injury Care Processes on Outcomes in Hospitalized Patients With Decompensated Cirrhosis.74
Folate and folic acid intake in relation to molecular subtypes of colorectal cancer: pooled analyses of up to 8970 cases and 8098 control participants.76
Metabolic Dysfunction as a Rising Barrier to HBV Elimination.72
Sedating Medications and the Risk of Falls, Hospitalizations, and Hepatic Encephalopathy in Cirrhosis: A Prospective Cohort.71
Effect of Dose Interval on Split-dose Bowel Preparation: A Multicenter Noninferiority Randomized Controlled Trial.75
Comparative Risk of Cancer with non-TNF Advanced Therapies Versus Anti-TNF Therapy in Inflammatory Bowel Disease.73
Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 48-week results from a multicentre, randomised, double-blind, phase 2b study.70
Nationwide Trends in Perioperative Transfusion and Mortality by Hospital Surgical Volume in Biliary Tract Surgery.74
Study rigorShiftPractice relevanceJournal standing